Literature DB >> 12852885

Predictors of outcome in patients with normal-pressure hydrocephalus.

Ullrich Meier1, Christoph Miethke.   

Abstract

Despite knowledge emerging over the last 40 years, the postoperative results after shunt implantation in patients diagnosed with normal-pressure hydrocephalus (NPH) have not improved significantly over the last decade. For that reason predictors have to be identified in order to preoperatively predict outcome. From 1982 to 2000 we prospectively studied 200 patients diagnosed with NPH. From the patients, who were surgically treated by a shunt implantation we reexamined 155 (78%) postoperatively a mean time interval of 7 months. The NPH was graded according to the results of the intrathecal infusion test in an early stage NPH (without brain atrophy) and late stage NPH (with brain atrophy). In our study, we focussed attention on the possible predictors: patients age, length of disease, clinical signs (gait ataxia, dementia and bladder incontinence), aetiology idiopathic/secondary as well as implanted valve type and the value of resistance to cerebrospinal fluid outflow. To measure the outcome we used the NPH recovery rate and as the statistical test the chi(2) according to Pearson. In 80 patients with an early stage NPH (without cerebral atrophy), a short course of disease (<1 year), a slight degree of dementia and an implanted Miethke-Dual-Switch valve were significant predictors for a positive postoperative outcome. The outflow resistance measured in the intrathecal infusion test showed only a minimal relevance to outcome. Those 75 patients with a late state NPH (with cerebral atrophy) had a better outcome when dementia was not present, the outflow resistance was above 20mm Hg/min/ml, the CSF tap-test was positive and a Miethke-Dual-Switch valve was implanted.

Entities:  

Mesh:

Year:  2003        PMID: 12852885     DOI: 10.1016/s0967-5868(03)00079-1

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  6 in total

1.  [Gravity valves for idiopathic normal pressure hydrocephalus. A Prospective study of 60 patients].

Authors:  U Meier
Journal:  Nervenarzt       Date:  2004-06       Impact factor: 1.214

2.  Differences in microstructural alterations of the hippocampus in Alzheimer disease and idiopathic normal pressure hydrocephalus: a diffusion tensor imaging study.

Authors:  Y J Hong; B Yoon; Y S Shim; A H Cho; S C Lim; K J Ahn; D W Yang
Journal:  AJNR Am J Neuroradiol       Date:  2010-07-29       Impact factor: 3.825

3.  Magnetic resonance spectroscopic determination of a neuronal and axonal marker in white matter predicts reversibility of deficits in secondary normal pressure hydrocephalus.

Authors:  A Shiino; Y Nishida; H Yasuda; M Suzuki; M Matsuda; T Inubushi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

4.  Differentiating shunt-responsive normal pressure hydrocephalus from Alzheimer disease and normal aging: pilot study using automated MRI brain tissue segmentation.

Authors:  Yafell Serulle; Henry Rusinek; Ivan I Kirov; Hannah Milch; Els Fieremans; Alexander B Baxter; John McMenamy; Rajan Jain; Jeffrey Wisoff; James Golomb; Oded Gonen; Ajax E George
Journal:  J Neurol       Date:  2014-08-01       Impact factor: 4.849

5.  Leucine-rich α-2-glycoprotein is a marker for idiopathic normal pressure hydrocephalus.

Authors:  Madoka Nakajima; Masakazu Miyajima; Ikuko Ogino; Maki Watanabe; Haruko Miyata; Kostadin L Karagiozov; Hajime Arai; Yoshiaki Hagiwara; Tatsuya Segawa; Kyoko Kobayashi; Yasuhiro Hashimoto
Journal:  Acta Neurochir (Wien)       Date:  2011-02-19       Impact factor: 2.216

Review 6.  Clinical predictors of shunt response in the diagnosis and treatment of idiopathic normal pressure hydrocephalus: a systematic review and meta-analysis.

Authors:  Santhosh G Thavarajasingam; Mahmoud El-Khatib; Mark Rea; Salvatore Russo; Johannes Lemcke; Lana Al-Nusair; Peter Vajkoczy
Journal:  Acta Neurochir (Wien)       Date:  2021-07-08       Impact factor: 2.216

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.